Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3LXE

Human Carbonic Anhydrase I in complex with topiramate

Summary for 3LXE
Entry DOI10.2210/pdb3lxe/pdb
DescriptorCarbonic anhydrase 1, ZINC ION, [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate, ... (4 entities in total)
Functional Keywordscarbonic anhydrase 1, topiramate, enzyme-inhibitor complex, lyase
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm: P00915
Total number of polymer chains2
Total formula weight58359.52
Authors
Alterio, V.,De Simone, G.,Monti, S.M.,Truppo, E. (deposition date: 2010-02-25, release date: 2010-07-21, Last modification date: 2023-11-01)
Primary citationAlterio, V.,Monti, S.M.,Truppo, E.,Pedone, C.,Supuran, C.T.,De Simone, G.
The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex.
Org.Biomol.Chem., 2010
Cited by
PubMed Abstract: Topiramate is a widely used antiepileptic drug, which has been demonstrated to act as an efficient weight loss agent. Since several studies have pointed out that is a potent in vitro inhibitor of several Carbonic anhydrase (CA) isozymes, it has been hypothesized that its anti-obesity properties could be ascribed to the inhibition of the CAs involved in de novo lipogenesis. Consequently, the study of the interactions of with all human CA isoforms represents an important step for the rational drug design of selective CA inhibitors to be used as anti-obesity drugs. In this paper we report the crystallographic structure of the adduct that forms with hCA I, showing for the first time a profound reorganization of the CA active site upon binding of the inhibitor. Moreover, a structural comparison with hCA II- and hCA VA- adducts, previously investigated, has been performed showing that a different H-bond network together with the movement of some amino acid residues in the active site may account for the different inhibition constants of toward these three CA isozymes.
PubMed: 20505865
DOI: 10.1039/b926832d
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

248335

PDB entries from 2026-01-28

PDB statisticsPDBj update infoContact PDBjnumon